Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 9/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16526395 | 0.94 | SMPD1 (0.51) | SMPD1DRD2DRD4DRD3GBA1 | |
| SCHEMBL16263567 | 0.92 | SMPD1 (0.54) | SMPD1DRD2DRD4DRD3GBA1 | |
| SCHEMBL14289745 | 0.92 | SMPD1 (0.54) | SMPD1DRD2DRD4DRD3GBA1 | |
| SCHEMBL2628202 | 0.87 | — | — | |
| SCHEMBL13469511 | 0.87 | SMPD1 (0.44) | SMPD1DRD2DRD4DRD3GBA1 | |
| SCHEMBL12386625 | 0.82 | DPP4 (0.43) | SMPD1DRD2DRD4DRD3GBA1 | |
| SCHEMBL19020573 | 0.82 | GBA1 (0.41) | SMPD1DRD2DRD4DRD3GBA1 | |
| SCHEMBL25831178 | 0.82 | DPP4 (0.47) | SMPD1DRD2DRD4DRD3GBA1 | |
| SCHEMBL24684592 | 0.81 | DPP4 (0.38) | SMPD1DRD2DRD4DRD3DPP4 | |
| SCHEMBL12386627 | 0.80 | DPP4 (0.42) | SMPD1DRD2DRD4DRD3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301129-A1 | SURFACE-FUNCTIONALIZED SILICON QUANTUM DOTS | THE CORETEC GROUP INC. | 2023-09-21 | — | — | US | disclosed |
| US-20200237924-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | KINETA CHRONIC PAIN, LLC (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2019199634-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | YALE UNIVERSITY (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20170319722-A1 | CD8-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | REGENERON PHARMACEUTICALS, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASE SE (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2229365-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077452-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | LIPA, IDE, CEL | SMPD1 1822/4885DRD2 3395/4885DRD4 3078/4885 |
| US-20200237924-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | CHRNG, CHRNA9, CHRNA10 | SMPD1 2415/4885DRD2 2390/4885DRD4 3658/4885 |
| US-20170319722-A1 | CD8-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CD81, CD4, CD69 | SMPD1 1926/4885DRD2 4760/4885DRD4 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.